Eli Lilly has recently reported promising results from a clinical trial for its gene-editing candidate, VERVE-102, which aims to treat conditions like familial hypercholesterolemia by significantly lowering LDL cholesterol levels with a one-time infusion. This positioning puts Lilly in potential competition with CRISPR Therapeutics, which focuses on similar cardiovascular issues with its gene-editing therapy, CTX310. While Eli Lilly is established in the weight-loss drug market with successful products like Zepbound and Foundayo, its foray into gene editing may present significant growth opportunities in an emerging therapeutic area. Investors face a choice between Eli Lilly, which offers stability and diversification, and CRISPR Therapeutics, a high-risk, high-reward option primarily centered on gene editing.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.theglobeandmail.com/investing/markets/stocks/NVDA/pressreleases/2274738/eli-lilly-just-proved-gene-editing-could-be-pharmas-next-gold-rush-but-crispr-therapeutics-investors-should-watch-out/
